Operations, Clinical Assessments and Adminstrative Core

运营、临床评估和管理核心

基本信息

  • 批准号:
    7645107
  • 负责人:
  • 金额:
    $ 97.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2011-06-30
  • 项目状态:
    已结题

项目摘要

The Operations, Clinical Assessment and Administrative Core oversees this entire project and is responsible for the conduct of the clinical trial and the collection of biological and behavioral data. Based on studies of groups of major depressive disorder (MDD) patients, any single psychotherapeutic or pharmacological strategy in clinical practice today achieves remission in only a minority of patients. Thus the initial treatment an individual with MDD receives is largely an accident of chance rather than an evidence based choice. Over a 5-year period, 400 treatment naive patients with MDD will be recruited into a 12 week treatment trial of randomly assigned treatment with an SSRI, escitalopram, a dual 5-HT/NE re-uptake inhibitor, duloxetine or cognitivebehavior therapy (CBT). Subjects will be evaluated using state-of-the-art clinical assessments prior to, during and at the end of acute treatment period. This core describes the efforts that will result in the identification, recruitment of the patients, and assessment and delivery of the treatments. A unique component of this proposal is the study of individuals with MDD not contaminated by previous treatments that may confound measures of treatment response. Commensurate with the CIDAR goals, the data generated in this core will provide the critical foundation for hypothesis generation and testing in the other cores and projects.
运营,临床评估和行政核心负责监督整个项目

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Helen S Mayberg其他文献

Posttraumatic Stress Disorder: A State-of-the-Science Review
创伤后应激障碍:最新科学回顾
  • DOI:
    10.1176/foc.7.2.foc254
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Charles B. Nemeroff;J. Bremner;Edna B Foa;Helen S Mayberg;Carol S. North;Murray B. Stein
  • 通讯作者:
    Murray B. Stein
Support Vector Machine Classification of Resting State fMRI Datasets Using Dynamic Network Clusters
使用动态网络集群对静息态 fMRI 数据集进行支持向量机分类
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Hyo Yul Byun;Helen S Mayberg
  • 通讯作者:
    Helen S Mayberg
The capacity of brain circuits to enhance psychiatry.
大脑回路增强精神病学的能力。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    B. Dunlop;Helen S Mayberg
  • 通讯作者:
    Helen S Mayberg
Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic
针对情绪和焦虑障碍中的异常神经回路:从实验室到临床
  • DOI:
    10.1038/nn1944
  • 发表时间:
    2007-08-28
  • 期刊:
  • 影响因子:
    20.000
  • 作者:
    Kerry J Ressler;Helen S Mayberg
  • 通讯作者:
    Helen S Mayberg

Helen S Mayberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Helen S Mayberg', 18)}}的其他基金

Establishing the anatomical and functional mechanisms of white matter deep brain stimulation
建立白质深部脑刺激的解剖和功能机制
  • 批准号:
    10803745
  • 财政年份:
    2023
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10604638
  • 财政年份:
    2022
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10647096
  • 财政年份:
    2022
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10310774
  • 财政年份:
    2021
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    9929246
  • 财政年份:
    2019
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    9869948
  • 财政年份:
    2017
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10768061
  • 财政年份:
    2017
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10545620
  • 财政年份:
    2017
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10547822
  • 财政年份:
    2017
  • 资助金额:
    $ 97.87万
  • 项目类别:
Electrophysiological Biomarkers to Optimize DBS for Depression
电生理生物标志物优化 DBS 治疗抑郁症
  • 批准号:
    10767494
  • 财政年份:
    2017
  • 资助金额:
    $ 97.87万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 97.87万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了